Click on image or enlarge button to enlarge
Nalmefene hydrochloride: sc-361270
Nalmefene hydrochloride (CAS 58895-64-0)
Alternate Names:
Nalmefene hydrochloride is also known as
Application:
Nalmefene hydrochloride is an opioid receptor antagonist
CAS Number:
58895-64-0
Molecular Weight:
375.89
Molecular Formula:
C21H25NO3•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Nalmefene hydrochloride has been reported to be an opioid receptor antagonist. The opioid family of G-protein-coupled receptors contains three types of opioids; μ opioid receptor (MOR), δ opioid receptor (DOR), and κ opioid receptor (KOR). Activating these receptors leads to the release of neurotransmitters such as dopamine, serotonin, and norepinephrine. Nalmefene hydrochloride has been studied for its various biological activities, including anti-inflammatory, anti-nociceptive, anticonvulsant, and neuroprotective effects.
References:
- Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys. | Mello, NK., et al. 2000. Pharmacol Biochem Behav. 66: 275-83. PMID: 10880679
- Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. | Chen, RZ., et al. 2004. Brain Res. 999: 227-30. PMID: 14759503
- Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. | Ingman, K., et al. 2005. Neuropsychopharmacology. 30: 2245-53. PMID: 15956985
- The permeation of nalmefene hydrochloride across different regions of ovine nasal mucosa. | Du, G., et al. 2006. Chem Pharm Bull (Tokyo). 54: 1722-4. PMID: 17139110
- In vivo characterization of the opioid antagonist nalmefene in mice. | Osborn, MD., et al. 2010. Life Sci. 86: 624-30. PMID: 20159022
- Potent inhibition of alcohol self-administration in alcohol-preferring rats by a kappa -opioid receptor antagonist. | Cashman, JR. and Azar, MR. 2014. J Pharmacol Exp Ther. 350: 171-80. PMID: 24817033
- In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene. | Xie, X., et al. 2015. PLoS One. 10: e0125953. PMID: 25938514
- Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. | Krieter, P., et al. 2019. J Pharmacol Exp Ther. 371: 409-415. PMID: 30940694
- Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice. | Zhou, Y. and Kreek, MJ. 2019. Brain Res. 1724: 146410. PMID: 31469985
- Effects of nalmefene hydrochloride on TLR4 signaling pathway in rats with lung ischemia-reperfusion injury. | Zhang, NL., et al. 2020. Eur Rev Med Pharmacol Sci. 24: 461-468. PMID: 31957861
- Naloxone and nalmefene absorption delivered by hollow microneedles compared to intramuscular injection. | Papich, MG. and Narayan, RJ. 2022. Drug Deliv Transl Res. 12: 376-383. PMID: 34817831
- Effect of Different Absorption Enhancers on the Nasal Absorption of Nalmefene Hydrochloride. | Zhang, T., et al. 2022. AAPS PharmSciTech. 23: 143. PMID: 35578146
- Sufentanil combined with nalmefene reduce the adverse events in recovery period of patients undergoing uvulopalatopharyngoplasty - A randomized controlled trial. | Wang, J., et al. 2023. Heliyon. 9: e13241. PMID: 36755590